TOP STORIES

• REGULATORY Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
  July 1, 2026

• COMMENTARY New Generic Listings Plunge, Industry Heads for a Shakeout
  July 1, 2026

• ORGANIZATION Incubator Led by Ex-Chugai CEO to Seek Govt Support, Raise Private Funds
  June 30, 2026

• REGULATORY Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
  June 30, 2026

• REGULATORY MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
  June 29, 2026

• BUSINESS Takeda Turns the Page to Kim’s “10-Year” Era, Betting on New Drugs and AI
  June 26, 2026

• REGULATORY Japan Targets Global-Level Growth for Domestic Patented Drug Market
  June 25, 2026

• BUSINESS Takeda Hands CEO Baton to Kim after 12-Year Weber Era
  June 24, 2026

• REGULATORY US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
  June 24, 2026

• BUSINESS Fycompa Generics Head for Summer Launch as Key Patent Expires
  June 23, 2026

• BUSINESS Lilly Japan Names Karla Alcazar as New President
  June 22, 2026

• REGULATORY Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
  June 22, 2026

• REGULATORY Japan on Alert over US MFN Drug Pricing Policy: Health Minister
  June 22, 2026

• REGULATORY LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
  June 19, 2026

• ORGANIZATION Japanese Drug Makers Step Up Use of ASEAN Reliance Reviews
  June 18, 2026

• BUSINESS Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
  June 18, 2026

• REGULATORY New Chuikyo Payer Rep Wary of Blanket Inflation Adjustment for Reimbursement
  June 17, 2026

• REGULATORY CEA Review Group Discusses Evidence for Additional Usefulness
  June 17, 2026

• REGULATORY Japan Sets 6-Billion-Yen Donation Target for Drug Discovery Fund
  June 17, 2026

• COMMENTARY Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
  June 16, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »